The TCN-202 is an antibody in development for the treatment of human cytomegalovirus (CMV) infection.
Theraclone Sciences CEO Clifford Stocks said TCN-202 was discovered using Theraclone’s I-STAR platform, which has demonstrated an ability to identify natural human antibodies with broad biologic activity and therapeutic potential.
"TCN-202 is directed against what we believe is a universal target within CMV variations, and this Phase 1 study is a significant step in bringing an important new treatment to patients with CMV infection," Stocks added.
The randomised study will provide safety, pharmacokinetic and immunogenicity data.
The double-blinded study will enrol up to 80 normal healthy volunteers at a single site in the US.
Theraclone anticipates study results in the first half of 2013.